Le Lézard
Classified in: Health, Covid-19 virus
Subject: EXE

Greater Philadelphia Region Seeks ARPA-H Home


Letter to HHS Secretary Points Out Region's Significant Assets

PHILADELPHIA, June 29, 2022 /PRNewswire/ -- The Chamber of Commerce for Greater Philadelphia today announced the region's intention to seek to be the new home for a recently announced $1 billion federal agency, the Advanced Research Projects Agency for Health (ARPA-H), which is expected to be located outside of Washington D.C.  In a letter sent to the U.S. Health & Human Services Department Secretary Xavier Becerra and signed by business, civic, and elected officials, signers tout the region's expertise in cell & gene therapy and gene editing, its rank as one of the top eight life sciences markets in the U.S., and its deep scientific and medical ecosystem as reasons why this area stands out as the ideal location. The new agency, established by Congress earlier this year, will speed up biomedical and health cures and treatment by funding new and innovative research.

Philadelphia Bids for ARPA-H HQ

"We feel that Greater Philadelphia's position as a global hub of research, talent, capital, and companies, combined with its second-to-none accessibility, give this region the power to forever transform how care is delivered to patients and essentially cure the incurable," the letter states.

The officials point out several assets in the eleven-county, tri-state region, including 15 health systems, 1,800 life sciences companies with more than 70,000 employees, nearly 50 cell & gene therapy companies doing landmark research, and headquarters for biopharmaceutical leaders including AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, and Merck. Capping off all these assets are the region's prominent research institutions. These institutions include the University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Coriell Institute, ChristianaCare's Gene Editing Institute, Drexel University, Jefferson Health, Temple University, and the Wistar Institute. All contribute to a steady stream of scientific discoveries and technical expertise; most notably the recent mRNA technology that serves as the foundation for both the Pfizer/BioNTech and Moderna COVID-19 vaccines. The subsector also benefits from a robust talent pipeline, with nearly 10,000 workers holding specific expertise in cell & gene therapy. 

"Today the Chamber is launching a multi-state, eleven-county regional effort to attract the new Advanced Research Projects Agency for Health to the Greater Philadelphia region," said Claire Marrazzo Greenwood, Executive Director and Senior Vice President of Economic Competitiveness for the Chamber. "The Chamber looks forward to continuing to build an even larger local coalition of supporters for this opportunity and to collaborating with federal, state, and local government officials in bringing ARPA-H's headquarters to our region."

The Philadelphia region has a long and deep track record of innovation. It is the home of the first FDA-approved cell therapy as well as the first FDA-approved gene therapy. To date, six FDA-approved cell & gene therapies have their origins in the region. Last year, the region attracted $12 billion in life sciences investment capital according to DealForma and was #1 in NIH grants received for cell & gene therapy companies.

Accessibility, given its central East Coast location, is an additional and significant regional asset. The letter states, "Our area serves as a global gateway accessible by air, sea, road, and both freight and inter-city passenger rail. Located directly adjacent to I-95 and only minutes from our major innovation hubs, Philadelphia International Airport (PHL) is easily accessible to our community, connects to more than 140 destinations worldwide and is already attracting life sciences companies that need proximity to an airport to move people and cargo ? as critical as living cells - to the lab, patient, or destination in a prompt and timely manner."

While the selection process for ARPA-H's new headquarters is not yet clear, local leaders are extending an invitation to the HHS Secretary to visit the region and to experience all of the benefits it has to offer as a potential new ARPA-H home.

 

SOURCE Chamber of Commerce for Greater Philadelphia


These press releases may also interest you

at 09:40
CF Energy Corp. ("CF Energy" or the "Company", together with its subsidiaries, the "Group"), an energy provider in the People's Republic of China (the "PRC" or "China"), announces that the Company has filed its audited consolidated financial results...

at 09:17
NanoAi Technologies, a company pioneering advancements in threat detection, today unveiled the NanoAi Technologies analyzer, a groundbreaking device designed to revolutionize security and safety measures across various sectors. This lightweight and...

at 09:05
First Eagle Investments ("First Eagle") is proud to announce the three-year anniversary of its First Eagle Small Cap Opportunity Fund (I-Share Class: FESCX). The Fund seeks long-term growth of capital by investing in small companies the portfolio...

at 09:00
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the implementation of a...

at 08:47
U.S. Gold Corp. ("U.S. Gold," the "Company," "we," "our" or "us") , today announced the results of the Company's annual shareholder meeting that was held virtually on April 26, 2024 at 9:00 AM MT....

at 08:45
The "Clinical Biomarkers Market - A Global and Regional Analysis: Focus on Offering, Clinical Area, Technology, End User, and Region - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global clinical...



News published on and distributed by: